The comparison between Efficacy of Treatment With Propranolol in Newborns With Retinopathy of Prematurity and control

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015102524681N1

Enrollment

Registered

2015-11-13

Start date

2015-11-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

Intervention 1: oral Propranolol (2 mg/kg/day divided in 4 doses for 26-31 weeks and 1mg/kg/day divided in 4 doses for 23-25 weeks) plus routine treatment. Intervention 2: outine treatment based on Op

Prevention

oral Propranolol (2 mg/kg/day divided in 4 doses for 26-31 weeks and 1mg/kg/day divided in 4 doses for 23-25 weeks) plus routine treatment

outine treatment based on Ophtalmologist recommendation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children with the diagnosis of retinopathy prematurity and lack of diseases such as any type of heart disease; low blood pressure; brain hemmorhage included in this study. Patients with severe complications of propranolol such as severe bradycardy or low blood pressure excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Grade of retinopathy. Timepoint: Each 2 weeks upto complete vascularization. Method of measurement: Grade of retinopathy 1-5.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reza Sharafi

Guilan University of Medical Science

rsharafi@gums.ac.ir+98 13 3336 9002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 6, 2026